AIM-quoted Motif has tested iclparim in patients with acute bacterial skin and skin structure infections (ABSSSI), for which it is now looking to get regulatory approval.
But the company has today signed an agreement with the Otto-von-Guericke University Magdeburg in Germany which is to carry out a series of lab tests to see if iclaprim can help people affected by toxoplasma chorioretinitis.
The orphan disease that is a type of ocular toxoplasmosis – a parasitic disease that may result in severe life-threatening infections and/or blindness.
The work will be carried out by professor Ildiko Rita Dunay, a director at the university’s Institute of Inflammation and Neurodegeneration.
“We are very pleased to work with Dr Dunay, who is an expert in the area of toxoplasmosis. In vitro data indicate that iclaprim has activity against toxoplasma,” said chief medical officer David Huang.
“The data generated from Dr Dunay's lab will be important in understanding whether iclaprim can play a role in this potentially devastating, progressive and recurring necrotizing retinitis, including vision-threatening complications.”